3 days Ago By ABMN Staff
Federated Hermes Inc. lowered its position in shares of Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY – Free Report ) by 37.
6% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 92,608 shares of the biopharmaceutical company’s stock after selling 55,896 shares during the quarter. Federated Hermes Inc.
owned about 0.07% of Alnylam Pharmaceuticals worth $22,504,000 at the end of the most recent quarter. A number of other large investors also recently bought and sold shares of ALNY.
Gilbert & Cook Inc. raised its position in shares of Alnylam Pharmaceuticals by 7.7% during the 4th quarter.
Gilbert & Cook Inc. now owns 4,443 shares of the biopharmaceutical company’s stock valued at $850,000 after acquiring an additional 317 shares in the last quarter. QRG Capital Management Inc.
acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $211,000. Dimensional Fund Advisors LP lifted its position in shares of Alnylam Pharmaceuticals by 6.0% in the 4th quarter.
Dimensional Fund Advisors LP now owns 267,034 shares of the biopharmaceutical company’s stock worth $51,126,000 after buying an additional 15,123 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 7.
0% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 89 shares during the period.
Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Alnylam Pharmaceuticals by 7.
0% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd.
now owns 56,144 shares of the biopharmaceutical company’s stock valued at $10,703,000 after buying an additional 3,665 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.
Alnylam Pharmaceuticals Stock Up 1.4 % Shares of Alnylam Pharmaceuticals stock opened at $265.27 on Monday.
The business has a fifty day simple moving average of $258.53 and a 200-day simple moving average of $195.09.
The firm has a market cap of $34.06 billion, a price-to-earnings ratio of -98.98 and a beta of 0.
38. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.
98 and a fifty-two week high of $287.55. Insiders Place Their Bets In other news, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction on Tuesday, August 20th.
The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00.
Following the completion of the sale, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink . In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the business’s stock in a transaction dated Tuesday, August 20th.
The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00.
Following the sale, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. The transaction was disclosed in a filing with the SEC, which is available through this link . Also, Director David E.
I. Pyott sold 32,450 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.
69, for a total transaction of $7,161,390.50. Following the completion of the transaction, the director now owns 136 shares of the company’s stock, valued at $30,013.
84. The disclosure for this sale can be found here . Over the last 90 days, insiders have sold 103,148 shares of company stock worth $25,658,824.
1.50% of the stock is owned by insiders. Analyst Upgrades and Downgrades A number of equities analysts have commented on the company.
BMO Capital Markets restated an “outperform” rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, June 24th. Bank of America boosted their price objective on Alnylam Pharmaceuticals from $295.
00 to $307.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. HC Wainwright reaffirmed a “buy” rating and issued a $400.
00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, August 30th. Barclays raised their target price on Alnylam Pharmaceuticals from $291.00 to $295.
00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. increased their price objective on shares of Alnylam Pharmaceuticals from $248.
00 to $280.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. Seven equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock.
Based on data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $279.14. Read Our Latest Stock Report on ALNY Alnylam Pharmaceuticals Company Profile ( Free Report ) Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. See Also Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc.
( NASDAQ:ALNY – Free Report ). Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
